D-半乳糖胺诱导肝衰竭肠源性内毒素血症模型最佳剂量选择  

The best dosage for modeling liver failure IETM induced by injecting D-gal

作　　者：周为[1] 陈斌[2] 彭杰[2] 李武[3] 苏煦初[4] 王杰[5] 徐嘉慰[5] 

机构地区：[1]重庆市中医院肝病科,重庆400021 [2]湖南中医药大学第一附属医院肝病科 [3]湖南中医药大学第一附属医院医学检验中心 [4]湖南中医药大学第一附属医院病理科 [5]湖南中医药大学研究生院

出　　处：《中西医结合肝病杂志》2014年第6期347-349,I0007,共4页Chinese Journal of Integrated Traditional and Western Medicine on Liver Diseases

基　　金：国家中医临床研究基地业务建设科研专项(No.JDZX2012062);湖南省科技厅科技计划(No.2013SK3105);湖南省中医药科研基金重点课题(No.201205)

摘　　要：目的:以D-半乳糖胺(D-gal)不同剂量腹腔注射诱导建立肝衰竭肠源性内毒素血症(IETM)实验动物模型,研究符合肝衰竭IETM改变的最佳造模剂量。方法:将SD大鼠随机分为正常组和D-gal低、中、高、超剂量组,D-gal低、中、高、超剂量组分别以不同剂量D-gal腹腔注射建立肝衰竭IETM模型,正常组在腹腔注射等量生理盐水后24h全部处死,观察D-gal各组大鼠在造模后24h、48h死亡率、肝功能、血清内毒素、肝组织及结肠组织病理等变化。结果:D-gal各组大鼠死亡率、肝功能、血清内毒素、肝组织及结肠组织损伤均明显高于正常组(P<0.01),且随D-gal剂量的增加而加重。结论:1腹腔注射D-gal可诱导建立肝衰竭IETM模型;2D-gal 1.8g/kg腹腔注射诱导建立的IETM模型符合肝衰竭IETM相关改变且更易于观察药物对IETM的干预作用。Objective： To reseach the optimal dosage of D-galactosamin （D-gal） for establishing liver failure IETM model induced by injecting D-gal. Methods： SD Rats were randomly divided into five groups： normal group and low, middle, high and ultra-dose group of D-gal. Rats in the low, middle, high and ultra-dose group of D-gal wre intraperitoneal inject different dose of D-gal to establish the model of IETM, normal group were put to death twenty-four hours after intraperitoneal injection of saline. After modeling 24h, 48h, the death rate of each group, the liver function （ALT, AST）, liver and intestinal histopathology, endotoxin in portal vein were inspected. Results： The death of each group, the liver function （ALT, AST）, liver and intestinal histopathology, endotoxin in portal vein were higher in different dose group of D-gal with the dosage of D-gal increasing the damage increased （P 〈 0. 01 ） . Conclusion： ①IETM model could be induced by inject D-gal intraperitonealy. ②Intraperitoneal inject D-gal at the dose of 1.8g/kg is not only well simulate related changes caused by IETM but easy to observe the intervention role of drug.

关 键 词：D-半乳糖胺 肝衰竭 肠源性内毒素血症 动物模型 

分 类 号：R575.3[医药卫生—消化系统] R-332[医药卫生—内科学]